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Edited by Francesc PosasAbstract The angiotensin I-converting enzyme (ACE) converts
the decapeptide angiotensin I (Ang I) into angiotensin II by
releasing the C-terminal dipeptide. A novel approach combining
enzymatic and electron paramagnetic resonance (EPR) studies
was developed to determine the enzyme eﬀect on Ang I contain-
ing the paramagnetic 2,2,6,6-tetramethylpiperidine-1-oxyl-4-
amino-4-carboxylic acid (TOAC) at positions 1, 3, 8, and 9.
Biological assays indicated that TOAC1-Ang I maintained
partly the Ang I activity, and that only this derivative and the
TOAC3-Ang I were cleaved by ACE. Quenching of Tyr4 ﬂuores-
cence by TOAC decreased with increasing distance between both
residues, suggesting an overall partially extended structure.
However, the local bend known to be imposed by the substituted
diglycine TOAC is probably responsible for steric hindrance, not
allowing the analogues containing TOAC at positions 8 and 9 to
act as substrates. In some cases, although substrates and prod-
ucts diﬀer by only two residues, the diﬀerence between their
EPR spectral lineshapes allows monitoring the enzymatic reac-
tion as a function of time.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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After its introduction in the early 1980s [1,2] for applications
in solid peptide chemistry method [3,4], the use of the cyclicAbbreviations: ACE, angiotensin I-converting enzyme; Aib, a-amino-
isobutyric acid; Ang I, angiotensin I; Ang II, angiotensin II; BK,
bradykinin; Boc, tert-butyloxycarbonyl; EPR, electron paramagnetic
resonance; Fmoc, 9-(ﬂuorenylmethyloxycarbonyl); PBC, phosphate-
borate-citrate buﬀer; LC/ESI-MS, liquid chromatography/electrospray
ionization mass spectrometry; HPLC, high-performance liquid chro-
matography; TFA, triﬂuoroacetic acid; TFE, 2,2,2-triﬂuoroethanol;
TOAC, 2,2,6,6-tetramethylpiperidine-1-oxyl-4-amino-4-carboxylic
acid
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doi:10.1016/j.febslet.2007.04.058and achiral 2,2,6,6-tetramethylpiperidine-1-oxyl-4-amino-4-
carboxylic acid (TOAC) spin probe [5] increased signiﬁcantly,
mainly after the introduction of an unconventional approach
which allows TOAC to be inserted at any position of the pep-
tide sequence [6]. Thereafter, a great variety of TOAC applica-
tions using mainly electron paramagnetic resonance (EPR)
spectroscopy were described in the literature.
Due to the fact that TOAC belongs to the same class of Ca,a-
disubstituted glycines as does aminoisobutyric acid (Aib), its
introduction into any peptide sequence will certainly produce
a unique structure as a consequence of its bend-forming capac-
ity. In this context, various authors have investigated in depth
the characteristics of the TOAC probe as well as its insertion
(single or double) into many types of model peptide sequences
[7–11] some of them of biological relevance [12–16]. Many
alternative experimental applications have been designed for
the use of this spin label, always taking into account its princi-
pal and more advantageous characteristics, i.e., of being rigidly
bound to a molecule or system and thus monitoring with more
sensitivity the dynamics of the site to which it is attached [17].
Some approaches are aimed to evaluate membranes [18,19] or
even the topology of integral membrane peptides [20], thus
providing examples of the broad range of applications for this
probe. In addition, its use has been also extended to the label-
ing of other systems such as those in which complex solvation
eﬀects of polymeric materials were investigated in order to im-
prove the peptide synthesis methodology [21–24].
In keeping with this trend toward developing novel uses for
the TOAC probe, we have initiated studies of an approach
where a peptide substrate labeled at diﬀerent positions with
the TOAC residue has been examined with regard to its spec-
iﬁcity for an enzyme. The system chosen as our model com-
prises the angiotensin I-converting enzyme (EC 3.4.15.1 or
ACE) and its substrate angiotensin I (Ang I, DRVYIHPFHL),
with the TOAC residue attached at positions 1, 3, 8, and 9.
Although the subject of many investigations and detailed
more thoroughly in a variety of reviews [25–28], some aspects
of the ACE functions in the organism have not as yet been fully
clariﬁed. This enzyme is a zinc-containing dipeptidyl
carboxypeptidase responsible for the conversion of the deca-
peptide Ang I to the potent vasoconstrictor octapeptide angio-
tensin II (Ang II) by hydrolyzing the Phe8-His9 peptide bond
[29], and for the degradation of the non-apeptide hypotensive
agent bradykinin (BK) [30], both important modulators ofblished by Elsevier B.V. All rights reserved.
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attempts to increase the understanding of the enzyme mecha-
nism, as well as the speciﬁcities of the substrate and inhibitor
[31–34].
In this context, the possibility of conjugating the investiga-
tion of ACE speciﬁcity for unusual substrates, i.e., Ang I ana-
logues containing TOAC at diﬀerent positions seems to be of
interest in order to simultaneously increase the knowledge of
this physiologically essential exopeptidase and determine the
eﬀect of the non-natural, cyclic TOAC residue on substrate
reactivity. Therefore, we synthesized these TOAC-bearing AI
analogues and developed the following experimental ap-
proaches: (i) determination of biological potency in contractile
tissues; (ii) conformational investigation by means of EPR and
ﬂuorescence spectroscopies; (iii) enzymatic assays of ACE and
determination of kinetic parameters; (iv) determination of
structure–activity relationships for the analogues in terms of
biological potency and substrate speciﬁcity; (v) time course
monitoring of ACE hydrolysis of labeled substrate analogues.2. Materials and methods
2.1. Material
The Boc and Fmoc amino acids were purchased from Bachem (Tor-
rance, CA, USA). Solvents and reagents were from Aldrich or Sigma
(St. Louis, MO, USA). Dimethylformamide was distilled over P2O5
and ninhydrin was distilled under reduced pressure before use. All sol-
vents were HPLC grade and all chemicals met ACS standards. Puriﬁed
rabbit lung ACE and lisinopril were purchased from Sigma. The molar
concentration of the enzyme was determined by active site titration
with lisinopril, as previously described [35].
2.2. Methods
2.2.1. Peptide synthesis. All peptides bearing the TOAC probe were
synthesized manually according to the combined Boc/Fmoc strategies
as previously reported [6]. All synthetic steps were performed through
Fmoc chemistry, and anhydrous HF (Boc chemistry) was used for re-
moval of the peptide from the solid support. The crude spin-labeled
peptides were submitted to alkaline treatment (pH 10, 1 h at 50 C)
for complete reversal of the N–O protonation that occurs during the
HF reaction [6,13]. Unlabeled peptides were synthesized using the
Boc strategy. The peptides were puriﬁed by preparative HPLC (C18-
column) using aqueous 0.02 M ammonium acetate (pH 5) and 60%
acetonitrile solutions as solvent A and B, respectively (linear gradient
of 30–70% B for 2 h, ﬂow rate of 10 mL/min). Peptide homogeneity
was determined through analytical HPLC, amino acid analysis and
LC/ESI-MS. The synthesized peptides were Ang I and its analogues
containing TOAC at positions 1, 3, 8, and 9. Ang II and its analogues
TOAC1-AII and TOAC3-AII were synthesized previously in our labo-
ratory [2,13].
2.2.2. EPR studies. Spectra were obtained at 9.5 GHz in a Bruker
ER 200 spectrometer at room temperature (22 ± 2 C) using ﬂat quartz
cells from Wilmad Glass Co., Buena, NJ, USA. The magnetic ﬁeld was
modulated with amplitudes less than one-ﬁfth the line widths, and the
microwave power was 5 mW to avoid saturation eﬀects. Rotational
correlation times, sB and sC, for pure reagents and products were cal-
culated from spectral line heights and line widths making use of the
equations given by Kivelson [36]. Only the latter parameter will be re-
ported here.
2.2.3. Fluorescence studies. Static ﬂuorescence spectra were ob-
tained at room temperature (22 ± 2 C) in a Hitachi F 2500 spectroﬂu-
orimeter (Hitachi, Tokyo), using cuvettes with excitation path lengths
of 2 mm or 5 mm and emission path lengths of 10 mm. Excitation and
emission slits were 5 nm. The excitation wavelength was 280 nm and
peptides concentrations were 104 M.
2.2.4. Mass spectrometry. The LC/ESI-MS experiments were per-
formed on a system consisting of a Waters Alliance model 2690 sepa-
rations module and model 996 photodiode array detector (Waters,
Eschborn, Germany) controlled with a Compaq AP200 workstationcoupled to a Micromass model ZMD mass detector (Micromass,
Altrincham, Cheshire, UK). The samples were automatically injected
on a Waters narrow bore Nova-Pak column C18 (2.1 · 150 mm, 60 A˚
pore size, 3.5 lm particle size). The elution was carried out with sol-
vents A (0.1% TFA/H2O) and B (60% acetonitrile/0.1% TFA/H2O)
at a ﬂow rate of 0.4 mL/min using a linear gradient from 5% to 95%
B in 30 min. The condition used for mass spectrometry measurements
was a positive ESI. Speciﬁcally for the case of monitoring enzymatic
reactions, a diﬀerent gradient of 35–50% (v/v) of solution B in
15 min, with ﬂow rate of 1.5 mL/min was used.
2.2.5. Amino acid analysis. Peptide composition was monitored
using amino acid analysis performed on a Biochrom 20 Plus amino
acid analyzer (Pharmacia LKB Biochrom Ltd., Cambridge, England)
equipped with an analytical cation-exchange column.
2.2.6. Determination of kinetic parameters for Ang I and TOAC-
containing peptides. The hydrolysis of peptides by puriﬁed rabbit lung
ACE was performed at 37 C in 0.1 M Tris–HCl buﬀer containing
50 mM NaCl and 10 lM ZnCl2 at pH 7.0 (1.0 mL ﬁnal volume).
The hydrolysis reaction was monitored by LC/ESI-MS as a function
of the time as already described, and the peaks areas were used for
determination of kinetic parameters. The enzyme concentration
(0.44 nM) was chosen so as to hydrolyze less than 5% of the substrate
present in order to obtain the initial rate. The peptide concentrations
(·105 M) were 1, 5, 10, 15 and 20. The hydrolysis reaction was inter-
rupted at diﬀerent times by adding TFA aquous solution until pH 3.5.
The kcat, Km and kcat/Km values were obtained by analysis of the non-
linear regression data using the GraFit program. The standard devia-
tion of these parameters was less than 5%.3. Results and discussion
Following a previously described experimental protocol [6],
the four paramagnetic AI analogues (labeling at positions 1,
3, 8, and 9) were obtained in satisfactory yield. The synthesis
scale for each sample was 0.2 mmol/g, and the general synthe-
sis and puriﬁcation protocol are detailed in Section 2.
3.1. Biological assays
To determine the biological properties of the paramagnetic
Ang I analogues, guinea pig ileum and rat uterus were chosen
as in vivo model systems for use in contraction experiments
[13]. It is well known that the biological potency of Ang I is
much lower than that of Ang II in tissues lacking suﬃcient
quantities of ACE needed to transform Ang I into Ang II. This
is the case of the rat uterus [37] where much lower activity is
expected for Ang I or its TOAC analogues in this type of mus-
cle preparation than in guinea pig ileum which contains ACE.
Accordingly, the biological potencies of Ang I in these two
muscle preparations were 1% and 11%, respectively, in com-
parison with those of Ang II, taken as 100%.
With regard to the paramagnetic analogues, only TOAC1-
Ang I maintained activity, presenting potency nearly two-times
in the uterus and 18% in guinea pig ileum that of Ang I. These
data represent relative activities of about 2% that of Ang II in
both muscle preparations, thus not in accordance with previ-
ous investigation of TOAC1-Ang II analogue where values
nearly 20% were determined in the two in vivo systems [13].
These ﬁndings reveal unknown factors aﬀecting the ACE
cleavage of Ang I to produce Ang II in these muscle contractile
assays, thus leaving the perspective of further more elaborated
investigations correlating in vitro and in vivo experiments.
Otherwise, the results are clearly in agreement with the previ-
ous observation that the N-terminal portion of Ang II (which
is responsible for muscle contraction) is less important for
maintaining its potency [38]. In particular, the lack of eﬀect
observed for TOAC3-AI is in agreement with previous studies
Fig. 2. EPR spectra of 104 M TOAC-labeled Ang I: (a) TOAC1-Ang
I, (b) TOAC3-Ang I, (c) TOAC8-Ang I and (d) TOAC9-Ang I in water,
pH 7.0.
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ing non-natural compounds such as TOAC [13], aminoisobu-
tyric acid [39] or 1-amino cyclopentane carboxylic acid [40]
led to a complete loss of activity of these analogues.
3.2. Fluorescence studies
Fig. 1 shows that the intramolecular quenching eﬀect of the
nitroxide group in TOAC upon the ﬂuorescence of the Tyr4
residue varies in the order: TOAC3-Ang I > TOAC1-Ang
I > TOAC8-Ang I > TOAC9-Ang I. The ﬂuorescence decrease
reached a maximum of approximately 70% for the TOAC3-
Ang I derivative, while TOAC9-Ang I presented approximately
the same ﬂuorescence intensity as native Ang I. These data
suggest that, in spite of the bend imposed by TOAC at the
local level, the peptides seem to exhibit partially extended
structures thus leading to stronger quenching when the nitrox-
ide is closer to Tyr4.
3.3. EPR studies
The EPR spectra of the TOAC-containing Ang I analogues
in water at pH 7.0 are given in Fig. 2. It can be seen that
TOAC3-Ang I and TOAC8-Ang I give rise to spectra with
broader linewidths, indicating that the motion at these posi-
tions is relatively more restricted. This is due to the fact that
more internal residues are expected to be less mobile and to
the known bend-inducing eﬀect of TOAC, a cyclic disubsti-
tuted glycine [14,16]. Accordingly, rotational correlation times
(sc) calculated for TOAC
3-Ang I and TOAC8-Ang I were of
the order of 7.0–7.5 · 1010 s, whereas sc values calculated
for TOAC1-Ang I and TOAC9-Ang I were 2 · 1010 s and
3.2 · 1010 s, respectively. These results are rather in agree-
ment with data obtained for TOAC-labeled Ang II and BK
analogues [13,14]. While the internally-labeled TOAC3-Ang
II and TOAC3-BK yielded sc values of approximately 5–
6 · 1010 s, their N-terminally labeled partners presented 2–3
times lower rotational correlation times. The unexpected high
mobility of TOAC9-Ang I might be attributable to a speciﬁc
conformation, which would allow for a greater freedom of mo-
tion, in particular at the C-terminal end.
3.4. Enzyme kinetics experiments
The four TOAC-bearing AI derivatives were assayed for
ACE activity, taking Ang I as the control substrate. The exper-Fig. 1. Fluorescence spectra of Ang I (104 M) and its TOAC-labeled
analogues in water, pH 7.0.imental procedure for determination of kinetic parameters is
given in Section 2. The progress of the hydrolysis reaction
was monitored through LC/ESI-MS of the components at
diﬀerent times (0, 15, 30, 60, 90, and 120 min). While
TOAC1-Ang I and TOAC3-Ang I were cleaved by ACE,
TOAC8-Ang I and TOAC9-Ang I, very likely owing to the fact
that the TOAC residue occupied separately, the two positions
of the scissile bond, were not. These ﬁndings conﬁrm the high
speciﬁcity of the ACE catalytic mechanism [41,42]. In particu-
lar, the bend imposed by TOAC probably creates steric con-
straints that also contribute to the lack of ﬁtting of the
substrates in the enzyme active site.
Table 1 displays the kinetic parameters determined for Ang I
and its two substrate analogues. These ﬁndings are in close
accordance with those already obtained for Ang I [43]; the data
suggest that ACE presents weaker hydrolytic activity upon
both analogues than on native Ang I. Comparatively, labeling
at position 1 yielded a better substrate than labeling at position
3. These data are in agreement with previous reports [41,42]
showing that the greater the distance of a mutated residue
from the cleavage site, the greater the probability of the
peptide to be cleaved by ACE. In addition, the bend generated
by TOAC at position 3 probably gives rise to a more rigid
conformation (as seen in TOAC3-Ang II and TOAC3-BK,
Table 1
Kinetic parameters for the hydrolysis of AI, TOAC1-Ang I and
TOAC3-Ang I by puriﬁed rabbit lung ACEa
Peptideb Km (lM) kcat (min
1) kcat/Km (lM
1 min1)
Ang I 30.8 472.7 15.5
TOAC1-Ang I 38.1 350.0 9.2
TOAC3-Ang I 47.2 153.7 3.2
aExperimental conditions: see Section 2.
bThe TOAC8-Ang I and TOAC9-Ang I were not hydrolyzed by ACE.
Fig. 3. Time course of the variation of the h0/h1 ratio in the EPR
spectra during the hydrolysis of TOAC3-Ang I (104 M) by puriﬁed
rabbit lung ACE, giving rise to TOAC3-Ang II.
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Ang I a less eﬃcient substrate for ACE.
The present data show that the insertion of TOAC and the
position at which it is inserted into the peptide sequence seem
to be important factors controlling the degree of enzymatic
cleavage. The results obtained for the Ang I labeled analogues
can be of value for designing better substrates or even inhibi-
tors, taking into account that, due to its structure, the TOAC
moiety can endow peptides with greater stability against prote-
ases.
Lastly, taking advantage of presence of the paramagnetic
TOAC moiety we investigate the feasibility of monitoring the
enzymatic hydrolysis through EPR spectroscopy in the case
of the peptides that still were ACE substrates. During the time
course of the enzymatic reaction a two-component spectrum is
obtained due to the contribution of the reagent, TOAC-labeled
Ang I, and the product, TOAC-labeled Ang II. In this case, the
EPR motional narrowing theory [44] precludes the rigorous
calculation of the s values due to the occurrence of a spectral
superposition. However since s is directly proportional to the
ratio h0/h1 (ratio of measured heights of the mid-ﬁeld and
high-ﬁeld lines), this empirical parameter was used to monitor
the progress of hydrolysis as previously done [1].
Due to its larger size, Ang I is expected to have a greater
rotational correlation time than Ang II, and, as a consequence,
the h0/h1 ratio in the spectra of Ang I analogues should be
higher. As the amount of product increases with time, this
ratio is expected to decrease. However, studies with TOAC1-
Ang I were not viable since this compound and its cleavage
product (TOAC1-Ang II) presented very similar spectra, thus
precluding monitoring the reaction by the variation of the h0/
h1 ratio during the enzymatic reaction. In contrast, it was pos-
sible to successfully apply this approach when TOAC3-Ang I
was the substrate, generating the corresponding TOAC3-Ang
II product. Fig. 3 shows the variation of the h0/h1 ratio during
the ACE-catalyzed hydrolysis of TOAC3-Ang I, using a four-
fold higher amount of enzyme with respect to the standard as-
say protocol, in order to lead the reaction to completeness. A
decrease in the h0/h1 ratio was observed as a function of time,
showing that the enzymatic reaction can be monitored by
means of EPR spectroscopy when reagent and product present
suﬃciently diﬀerent spectra. It is noteworthy that this diﬀerence
does not have to be too large to allow for the use of this meth-
odology. A more elaborated investigation aiming to verifying
the type of relationship existing between enzyme catalytic val-
ues with those of some existing EPR spectral mobility parame-
ters might be further developed but with the need of a much
larger amount of data originated from experiments comprising
other enzyme-paramagnetic substrate sets.
In summary, this objective of this study was to lay the
groundwork for a novel line of research: the investigation ofthe speciﬁcity of enzymes for substrates carrying the paramag-
netic and non-natural amino acid TOAC. This strategy has
multiple goals, ranging from the determination of the confor-
mational properties of the labeled peptide analogues to ascer-
taining their biological and enzymatic activity and, ﬁnally, to
characterize, through a structure–function approach, the rela-
tionship between these properties. In this context, ACE and its
substrate Ang I carrying the TOAC spin probe were selected as
models for this initial eﬀort, with the scope of applying this ap-
proach to other proteases and their respective substrates in the
future. The results obtained with the four labeled Ang I coun-
terparts should, in conjunction with complementary studies,
further the understanding of the ACE catalytic mechanism.
Thus, besides being able to report on the dynamics and confor-
mation of TOAC-labeled compounds, the present study shows
that EPR spectroscopy can also contribute to studies of en-
zyme-catalyzed peptide reactions.
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